DMTs and Covid‐19 severity in MS: a pooled analysis from Italy and France - Sorbonne Université Accéder directement au contenu
Article Dans Une Revue Annals of Clinical and Translational Neurology Année : 2021

DMTs and Covid‐19 severity in MS: a pooled analysis from Italy and France

1 UniGe - Università degli studi di Genova = University of Genoa
2 UNIROMA - Università degli Studi di Roma "La Sapienza" = Sapienza University [Rome]
3 CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier]
4 LilNCog - Lille Neurosciences & Cognition - U 1172
5 Fondation Ophtalmologique Adolphe de Rothschild [Paris]
6 Azienda Socio Sanitaria Territoriale Spedali Civili di Brescia [Brescia]
7 TIMONE - Hôpital de la Timone [CHU - APHM]
8 HCL - Hospices Civils de Lyon
9 IRCCS Ospedale San Raffaele [Milan, Italy]
10 CHL - Centre Hospitalier de Luxembourg [Luxembourg]
11 Azienda Ospedaliera Ospedale Papa Giovanni XXIII [Bergamo, Italy]
12 UNIL - Université de Lausanne = University of Lausanne
13 CHUGA - Centre Hospitalier Universitaire [CHU Grenoble]
14 CHU Toulouse - Centre Hospitalier Universitaire de Toulouse
15 UNIBA - Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro
16 ICM - Institut du Cerveau = Paris Brain Institute
17 CHU Saint-Antoine [AP-HP]
18 Service de neurologie [Mondor]
19 Università degli studi della Campania "Luigi Vanvitelli" = University of the Study of Campania Luigi Vanvitelli
20 CHU Clermont-Ferrand
21 CHU Nîmes - Centre Hospitalier Universitaire de Nîmes
22 IGF - Institut de Génomique Fonctionnelle
23 UNISI - Università degli Studi di Siena = University of Siena
24 CHU Dijon - Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand
25 Unict - Università degli studi di Catania = University of Catania
26 Centre d’Investigation Clinique Plurithématique (CIC - P) - CIC Strasbourg
27 CIC Neurosciences - Centre d'investigation clinique Neurosciences [CHU Pitié Salpêtrière]
Jean Pelletier
Sandra Vukusic
Paolo Immovilli
  • Fonction : Auteur
Marco Capobianco
  • Fonction : Auteur
Jérôme de Sèze
  • Fonction : Auteur

Résumé

We evaluated the effect of DMTs on Covid-19 severity in patients with MS, with a pooled-analysis of two large cohorts from Italy and France. The association of baseline characteristics and DMTs with Covid-19 severity was assessed by multivariate ordinal-logistic models and pooled by a fixed-effect meta-analysis. 1066 patients with MS from Italy and 721 from France were included. In the multivariate model, anti-CD20 therapies were significantly associated (OR = 2.05, 95%CI = 1.39-3.02, p < 0.001) with Covid-19 severity, whereas interferon indicated a decreased risk (OR = 0.42, 95%CI = 0.18-0.99, p = 0.047). This pooled-analysis confirms an increased risk of severe Covid-19 in patients on anti-CD20 therapies and supports the protective role of interferon.
Fichier principal
Vignette du fichier
acn3.51408.pdf (298.92 Ko) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-03285034 , version 1 (13-07-2021)

Licence

Paternité - Pas d'utilisation commerciale - Pas de modification

Identifiants

Citer

Maria Pia Sormani, Marco Salvetti, Pierre Labauge, Irene Schiavetti, Helene Zephir, et al.. DMTs and Covid‐19 severity in MS: a pooled analysis from Italy and France. Annals of Clinical and Translational Neurology, 2021, 8 (8), pp.1738-1744. ⟨10.1002/acn3.51408⟩. ⟨hal-03285034⟩
92 Consultations
124 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More